P1‐046: Clinical and pathological features of frontotemporal lobar degeneration with FUS‐positive inclusions

to conventional pharmacotherapy. We studied a specific omega-3 fatty acid, the ethyl ester of eicosapentaenoic acid (E-EPA), as an adjunct to antidepressant treatment for episodes of depressive disorder occurring in older depressed patients(over 60 years old) with or without executive dysfunction. Methods: The design was a 12-week, parallel-group, double-blind addition of E-EPA or placebo to ongoing antidepressant therapy. Patients continued their current antidepressant treatment at the same dose they were receiving when they entered the study. The E-EPA or matching placebo was given in 1-g doses twice a day for a total of 2 g/day. Executive functions were assessed with Controlled Oral Word Association Test and the Korean Stroop Color-Word Test and Trail Making Test part B. Depressive symptoms were measured by Korean Geriatric depression Scale(K-GDS), Quick Inventory of Depressive Symptomtology-Self Report(QIDS-SR). Results: Eighty six patients participated. A total of 52 patients completed the study. At endpoint (12 weeks), the mean change from baseline in QIDS-SR total score was -20.2 for patients treated with placebo (n1⁄4 23) and -23.5 for patients with EEPA (n1⁄4 29), resulting in no difference. But, both abnormal Controlled oral word association test and abnormal Stroop Color-Word scores were associated with an favorable response of geriatric depression to E-EPA addition treatment. Conclusions: Improvement of frontal lobe dysfunction were found after supplementation of omega-3 fatty acid in geriatric depressive patients with executive dysfunction.